# OnCo record radionuclide-parp-combination (technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/technologies/radionuclide-parp-combination/>
  a schema:MedicalTherapy ;
  onco:kind "technology" ;
  schema:identifier "radionuclide-parp-combination" ;
  schema:name "Radioligand plus DNA-repair inhibitor combinations"@en ;
  schema:description "Adding a PARP or ATR inhibitor to a radioactive drug so the tumour cannot repair the damage the radiation causes."@en ;
  schema:url <https://onco.cc/technologies/radionuclide-parp-combination/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?term=lutetium%20PSMA%20olaparib> ;
  onco:status "phase-1" ;
  onco:tag "frontier", "promising" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/neuroendocrine/> ;
  onco:sections <https://onco.cc/fronts/radiopharma/>, <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/targeted-alpha-therapy/> ;
  onco:targets <https://onco.cc/targets/parp/>, <https://onco.cc/targets/psma/>, <https://onco.cc/targets/sstr2/>, <https://onco.cc/targets/atr/> .